Get the Stockscreener App
6.10
0.16%
-0.01
After Hours:
6.10
Organon Co stock is traded at $6.10, with a volume of 3.74M.
It is down -0.16% in the last 24 hours and down -18.77% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$6.11
Open:
$6.22
24h Volume:
3.74M
Relative Volume:
0.75
Market Cap:
$1.59B
Revenue:
$6.22B
Net Income/Loss:
$187.00M
P/E Ratio:
8.5124
EPS:
0.7166
Net Cash Flow:
$508.00M
1W Performance:
-2.09%
1M Performance:
-18.77%
6M Performance:
-39.72%
1Y Performance:
-58.56%
1-Day Range:
$6.025
$6.23
1-Week Range:
$5.76
$6.31
52-Week Range:
$5.76
$14.94
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.10 | 1.59B | 6.22B | 187.00M | 508.00M | 0.7166 |
LLY
Lilly Eli Co
|
916.31 | 806.39B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.93 | 566.67B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.18 | 362.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.37 | 287.71B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
187.14 | 288.11B | 58.80B | 10.24B | 8.98B | 3.2788 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon & Co stock faces renewed scrutiny amid women's health sector shifts and pipeline updates - AD HOC NEWS
Organon sees opportunities in China's push for high-quality population development - China Daily
Organon & Co. Stock Plummets to New 52-Week Low of $5.76 - Markets Mojo
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Organon: A High Cash Yield Hidden Behind Patent Fatigue - TradingView
Organon & Co. (NYSE:OGN) Hits New 52-Week LowHere's Why - MarketBeat
Organon & Co. Hits New 52-Week Low at USD 6.16 Amidst Declining Performance - Markets Mojo
Assessing Organon (OGN) Valuation After Prolonged Share Price Weakness And A 33% Undervaluation Estimate - simplywall.st
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? - The Motley Fool
Does a $25 Million Investment in a Stock That Has Fallen 61% Indicate a Possible Recovery at $6? - Bitget
Sio Capital's New Organon Investment: A Value Play in Women's HealthNews and Statistics - IndexBox
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? - The Motley Fool
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility - MSN
Behavioral Patterns of OGN and Institutional Flows - Stock Traders Daily
Organon & Co stock hits 52-week low at 6.17 USD By Investing.com - Investing.com South Africa
Organon & Co stock hits 52-week low at 6.17 USD - Investing.com Australia
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility (IJR:NYSEARCA) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 12-Month LowHere's Why - MarketBeat
Organon rises after update on independent review - MSN
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Investors heavily search Organon & Co. (OGN): Here is what you need to know - MSN
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Aug Wrap: Can Organon Co expand into new marketsWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence - Markets Mojo
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Organon & Co. (OGN) Dividend Yield 2026, Date & History $OGN - MarketBeat
OGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon trades in red for seven straight sessions - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm
Organon Stock Tumbles To Record Low On Downgrades And Dividend Cut: Retail Optimism Persists - MSN
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Royce & Associates LP Trims Position in Organon & Co. $OGN - MarketBeat
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
1.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):